This fat loss stack combines three peptides that target adipose tissue through distinct biological mechanisms: semaglutide reduces caloric intake through appetite suppression and GLP-1 signaling, AOD-9604 promotes lipolysis through a GH-fragment mechanism without GH's metabolic side effects, and tesamorelin stimulates endogenous GH release to specifically target visceral adipose tissue.
The theoretical advantage of combining these peptides is mechanistic diversity — rather than maximizing a single pathway (appetite suppression alone or GH elevation alone), the stack addresses multiple drivers of fat accumulation simultaneously. Each peptide has a different evidence base: semaglutide has robust Phase 3 clinical trial data, tesamorelin is FDA-approved for a specific fat-related indication, and AOD-9604 has more limited clinical evidence.
Important: Combining these peptides together has not been studied in any clinical trial. Semaglutide and tesamorelin are prescription medications with specific approved indications. AOD-9604 is a research compound without FDA approval. Any multi-peptide fat loss protocol should be supervised by a physician. This guide is for educational purposes only and does not constitute medical advice.
Rather than maximizing a single pathway, the stack addresses multiple drivers of fat accumulation simultaneously.
The peptides
Why these work together
This stack targets fat through three independent biological pathways. Semaglutide activates GLP-1 receptors in the hypothalamus, reducing appetite and food reward signaling, while also delaying gastric emptying to increase satiety after meals. The net effect is a sustained caloric deficit — the primary driver of fat loss — achieved without the hunger and cravings that typically undermine dietary restriction.
AOD-9604 acts on fat cells through a fragment of the GH receptor, stimulating the breakdown of stored triglycerides (lipolysis) and inhibiting the formation of new fat (lipogenesis). Crucially, it does not activate the full GH receptor, so it avoids GH's effects on blood glucose, insulin resistance, and tissue growth. This makes it a targeted lipolytic agent rather than a broad metabolic stimulant.
Tesamorelin stimulates the pituitary to release endogenous GH, which has a well-established role in mobilizing visceral fat. FDA-approval data in HIV lipodystrophy patients showed significant reduction in visceral adipose tissue area (approximately 15-18% reduction). Its mechanism complements semaglutide (which works through appetite/CNS pathways) and AOD-9604 (which works through a GH-fragment pathway) because endogenous GH release also promotes fatty acid oxidation through hepatic and systemic effects.
Suggested protocol
Begin with semaglutide alone following the Wegovy titration schedule. Establishes GI tolerance and baseline appetite response before introducing additional compounds.
Continue semaglutide titration (now 0.5 mg weekly). Introduce AOD-9604 for direct lipolytic action. Staggered introduction isolates side effects to their source.
All three peptides active. Tesamorelin targets visceral fat via endogenous GH. Monitor blood glucose, insulin, and IGF-1 — both tesamorelin and semaglutide affect glucose metabolism.
All compounds at stabilized doses. Semaglutide may titrate up to 2.4 mg per Wegovy schedule. Tesamorelin body composition changes become significant around week 12.
Safety considerations
Common: nausea, vomiting, diarrhea (especially during titration). Rare: pancreatitis, thyroid C-cell tumors (rodent studies). Contraindicated with MEN 2 syndrome or pancreatitis history.
Generally well-tolerated in early trials. Reported: headache, injection site irritation. Limited long-term safety data — did not complete full regulatory approval.
Common: joint pain, peripheral edema, injection site reactions. May raise IGF-1 levels and affect glucose homeostasis. Monitor blood glucose and IGF-1.
The combination of all three peptides has never been studied in clinical trials. Additive side effects, drug interactions, and long-term safety are unknown. Not appropriate for individuals with active or prior pancreatitis, MEN 2 syndrome, active cancer, or during pregnancy/breastfeeding. Physician supervision is essential.
Frequently asked questions
This specific three-peptide combination has not been studied in any clinical trial. While each peptide works through a different mechanism (appetite suppression, lipolysis, GH-mediated fat mobilization), the interaction effects of combining them are unknown. Any multi-peptide protocol should be supervised by a physician who can monitor metabolic markers and adjust dosing.
Semaglutide is the primary driver of weight loss in this stack, with Phase 3 data showing 15-17% body weight reduction as a single agent. Tesamorelin specifically targets visceral fat (15-18% reduction in clinical studies). AOD-9604 has the least clinical weight loss data. The stack's theory is that combining all three provides broader fat reduction than any single agent.
Semaglutide (Wegovy) and tesamorelin (Egrifta) are both prescription medications requiring a physician's order. AOD-9604 is not FDA-approved and is available only as a research compound. The full stack requires medical supervision regardless of the acquisition path for individual components.
The most common side effects come from semaglutide: nausea, vomiting, and diarrhea, especially during dose titration. Tesamorelin can cause joint pain, peripheral edema, and injection site reactions. AOD-9604 side effects are less well-characterized but reports include headache and injection site irritation. Blood glucose changes should be monitored since semaglutide and tesamorelin both affect glucose metabolism.
Appetite suppression from semaglutide typically begins within 1-2 weeks. Measurable weight loss appears within the first month. Body composition changes from tesamorelin (visceral fat reduction) take 8-12 weeks to become significant based on clinical trial data. The full stack is designed for 12-24 week protocols with physician monitoring of metabolic biomarkers.